New Market Research Report: NPS+ Renal Cell Carcinoma (US)

Two brands lead the RCC treatment market. How does your brand stack up?

US oncologists may not be totally satisfied with available renal cell carcinoma (RCC) treatments, but two brands have earned high satisfaction scores and pulled ahead of the rest. Find out which two, and see how your brand measures up./paragraph>FirstView's NPS+ Renal Cell Carcinoma report compares brand loyalty for 8 major RCC treatments-information you can use to improve your brand's health, and boost your market share./paragraph>Based on your brand's net promoter score (NPS), the report shows you how likely doctors are to recommend your brand, which of your competitors they recommend, and which promotional messages drive those recommendations. Plus you'll learn how doctors really perceive your brand./Paragraph>Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear./Paragraph>Interested in the European market? Click here to see the EU5 Edition./Paragraph>Get Answers to Key Questions about RCC Treatments

Full Report Details at
- http://www.fastmr.com/prod/1152008_nps+_renal_cell_carcinoma_us.aspx?afid=301

* Afinitor (everolimus; Novartis): Does its brand DNA reveal what oncologists think about the future of Afinitor?
* Avastin (bevacizumab; Roche): Are Avastin Detractors more likely to recommend Inlyta or Opdivo?
* Inlyta (axitinib; Pfizer): What does Inlyta's brand DNA reveal about where it fits into the RCC treatment paradigm?
* Opdivo (nivolumab; Bristol-Myers Squibb): Oncologists speak highly of Opdivo's novel mechanism of action. Does that translate into recommendations?
* Proleukin (aldesleukin; Prometheus): Are toxicity concerns preventing Proleukin detractors from recommending it?
* Sutent (sunitinib malate; Pfizer): Which three brand messages resonate with Sutent Promoters, Passives, and Detractors?
* Torisel (temsirolimus; Pfizer): What does brand DNA reveal about the patient population best suited for Torisel?
* Votrient (pazopanib; Novartis): Votrient has one of the highest market shares among Promoters. Which brand is it tied with?

Top Takeaways

* Two brands lead the pack: While half of the surveyed brands have a positive NPS, the top two score 2-3 times higher than the nearest competitor.
* Satisfaction is moderate, but higher than in Europe: In the US, over 70% of oncologists surveyed are satisfied with available RCC drugs. In Europe, the figure is under 65%.
* Oncologists are optimistic about new treatments: Low market share notwithstanding, one recently-approved brand gets high praise for innovation.
* Exclusivity is relatively high: More than 20% of oncologists surveyed promote one brand exclusively.
* Cost is a concern, but not for all brands: Although clinical attributes remain the key drivers of doctor recommendations, cost is important for half of the brands surveyed.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS+ Renal Cell Carcinoma (EU5)
- Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
- Renal Cell Carcinoma - Pipeline Review, H2 2015
- Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2016
- Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015